The University of Chicago Header Logo

Connection

Kenneth Polonsky to C-Peptide

This is a "connection" page, showing publications Kenneth Polonsky has written about C-Peptide.
Connection Strength

2.470
  1. Basal and glucagon-stimulated plasma C-peptide concentrations in healthy dogs, dogs with diabetes mellitus, and dogs with hyperadrenocorticism. J Vet Intern Med. 1996 May-Jun; 10(3):116-22.
    View in: PubMed
    Score: 0.125
  2. Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance. J Clin Endocrinol Metab. 1993 Jan; 76(1):44-8.
    View in: PubMed
    Score: 0.099
  3. Alterations in the kinetics of C-peptide and insulin secretion in hyperthyroidism. J Clin Endocrinol Metab. 1993 Jan; 76(1):79-84.
    View in: PubMed
    Score: 0.099
  4. Xenin-25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes. Diabetes. 2012 Jul; 61(7):1793-800.
    View in: PubMed
    Score: 0.094
  5. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes. 1992 Mar; 41(3):368-77.
    View in: PubMed
    Score: 0.094
  6. Lack of effect of high-dose biosynthetic human C-peptide on pancreatic hormone release in normal subjects. Metabolism. 1990 Aug; 39(8):827-32.
    View in: PubMed
    Score: 0.084
  7. TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes. 2010 Feb; 59(2):479-85.
    View in: PubMed
    Score: 0.080
  8. Peripheral insulin parallels changes in insulin secretion more closely than C-peptide after bolus intravenous glucose administration. J Clin Endocrinol Metab. 1988 Nov; 67(5):1094-9.
    View in: PubMed
    Score: 0.074
  9. Reduction of insulin clearance during hyperglycemic clamp. Dose-response study in normal humans. Diabetes. 1988 Oct; 37(10):1351-7.
    View in: PubMed
    Score: 0.074
  10. Reevaluation of urine C-peptide as measure of insulin secretion. Diabetes. 1988 Sep; 37(9):1195-201.
    View in: PubMed
    Score: 0.073
  11. Standardization of C-peptide measurements. Clin Chem. 2008 Jun; 54(6):1023-6.
    View in: PubMed
    Score: 0.072
  12. Quantitative study of insulin secretion and clearance in normal and obese subjects. J Clin Invest. 1988 Feb; 81(2):435-41.
    View in: PubMed
    Score: 0.070
  13. Calculated pattern of intraportal insulin appearance without independent assessment of C-peptide kinetics. Diabetes. 1987 Oct; 36(10):1195-202.
    View in: PubMed
    Score: 0.069
  14. International comparison of C-peptide measurements. Clin Chem. 2007 Apr; 53(4):784-7.
    View in: PubMed
    Score: 0.066
  15. The limitations to and valid use of C-peptide as a marker of the secretion of insulin. Diabetes. 1986 Apr; 35(4):379-86.
    View in: PubMed
    Score: 0.062
  16. Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. J Clin Invest. 1986 Jan; 77(1):98-105.
    View in: PubMed
    Score: 0.061
  17. Current approaches to measurement of insulin secretion. Diabetes Metab Rev. 1986; 2(3-4):315-29.
    View in: PubMed
    Score: 0.061
  18. C-peptide and insulin secretion. Relationship between peripheral concentrations of C-peptide and insulin and their secretion rates in the dog. J Clin Invest. 1984 Nov; 74(5):1821-9.
    View in: PubMed
    Score: 0.056
  19. C-peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations. Diabetes. 1984 May; 33(5):486-94.
    View in: PubMed
    Score: 0.054
  20. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes. 2004 Jan; 53(1):250-64.
    View in: PubMed
    Score: 0.053
  21. Metabolism of C-peptide in the dog. In vivo demonstration of the absence of hepatic extraction. J Clin Invest. 1983 Sep; 72(3):1114-23.
    View in: PubMed
    Score: 0.052
  22. Insulin secretory responses to rising and falling glucose concentrations are delayed in subjects with impaired glucose tolerance. Diabetologia. 2002 Apr; 45(4):509-17.
    View in: PubMed
    Score: 0.047
  23. Quantitative indexes of beta-cell function during graded up&down glucose infusion from C-peptide minimal models. Am J Physiol Endocrinol Metab. 2001 Jan; 280(1):E2-10.
    View in: PubMed
    Score: 0.043
  24. Altered insulin secretory responses to glucose in diabetic and nondiabetic subjects with mutations in the diabetes susceptibility gene MODY3 on chromosome 12. Diabetes. 1996 Nov; 45(11):1503-10.
    View in: PubMed
    Score: 0.032
  25. Insulin secretion in insulin-resistant women with a history of gestational diabetes. Metabolism. 1995 Aug; 44(8):1067-73.
    View in: PubMed
    Score: 0.030
  26. Lilly Lecture 1994. The beta-cell in diabetes: from molecular genetics to clinical research. Diabetes. 1995 Jun; 44(6):705-17.
    View in: PubMed
    Score: 0.029
  27. Alterations in the patterns of insulin secretion before and after diagnosis of IDDM. Diabetes Care. 1995 Apr; 18(4):568-71.
    View in: PubMed
    Score: 0.029
  28. Alterations in immunoreactive proinsulin and insulin clearance induced by weight loss in NIDDM. Diabetes. 1994 Jul; 43(7):871-7.
    View in: PubMed
    Score: 0.027
  29. Xenin-25 delays gastric emptying and reduces postprandial glucose levels in humans with and without type 2 diabetes. Am J Physiol Gastrointest Liver Physiol. 2014 Feb 15; 306(4):G301-9.
    View in: PubMed
    Score: 0.026
  30. Prior feeding alters the response to the 50-g glucose challenge test in pregnancy. The Staub-Traugott effect revisited. Diabetes Care. 1993 Dec; 16(12):1551-6.
    View in: PubMed
    Score: 0.026
  31. Lack of control by glucose of ultradian insulin secretory oscillations in impaired glucose tolerance and in non-insulin-dependent diabetes mellitus. J Clin Invest. 1993 Jul; 92(1):262-71.
    View in: PubMed
    Score: 0.026
  32. Quantitative evaluation of the effect of low-intensity exercise on insulin secretion in man. Metabolism. 1993 Jul; 42(7):829-33.
    View in: PubMed
    Score: 0.026
  33. Oscillatory insulin secretion after pancreas transplant. Diabetes. 1993 Jun; 42(6):855-61.
    View in: PubMed
    Score: 0.025
  34. Defects in beta-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metab. 1993 May; 76(5):1241-7.
    View in: PubMed
    Score: 0.025
  35. Analytical problems in detecting rapid insulin secretory pulses in normal humans. Am J Physiol. 1993 Feb; 264(2 Pt 1):E231-8.
    View in: PubMed
    Score: 0.025
  36. Insulin secretory profiles and C-peptide clearance kinetics at 6 months and 2 years after kidney-pancreas transplantation. Diabetes. 1992 Oct; 41(10):1346-54.
    View in: PubMed
    Score: 0.024
  37. Fasting hypertriglyceridemia in noninsulin-dependent diabetes mellitus is an important predictor of postprandial lipid and lipoprotein abnormalities. J Clin Endocrinol Metab. 1991 Apr; 72(4):934-44.
    View in: PubMed
    Score: 0.022
  38. Entrainment of pulsatile insulin secretion by oscillatory glucose infusion. J Clin Invest. 1991 Feb; 87(2):439-45.
    View in: PubMed
    Score: 0.022
  39. Effect of glyburide on beta cell responsiveness to glucose in non-insulin-dependent diabetes mellitus. Am J Med. 1990 Aug 20; 89(2A):11S-16S; discussion 51S-53S.
    View in: PubMed
    Score: 0.021
  40. Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1989 Sep; 69(3):571-6.
    View in: PubMed
    Score: 0.020
  41. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med. 1988 May 12; 318(19):1231-9.
    View in: PubMed
    Score: 0.018
  42. Weight loss therapy improves pancreatic endocrine function in obese older adults. Obesity (Silver Spring). 2008 Jun; 16(6):1349-54.
    View in: PubMed
    Score: 0.018
  43. Dose-dependent effects of oral and intravenous glucose on insulin secretion and clearance in normal humans. Am J Physiol. 1988 Mar; 254(3 Pt 1):E349-57.
    View in: PubMed
    Score: 0.018
  44. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest. 1988 Feb; 81(2):442-8.
    View in: PubMed
    Score: 0.018
  45. Insulin Wakayama: familial mutant insulin syndrome in Japan. Diabetologia. 1987 Feb; 30(2):87-92.
    View in: PubMed
    Score: 0.016
  46. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006 Sep 28; 355(13):1318-30.
    View in: PubMed
    Score: 0.016
  47. Ingestion of a mixed meal does not affect the metabolic clearance rate of biosynthetic human C-peptide. J Clin Endocrinol Metab. 1986 Aug; 63(2):401-3.
    View in: PubMed
    Score: 0.016
  48. The measurement and validation of the nonsteady-state rates of C-peptide appearance in the dog. Diabetologia. 1986 Jul; 29(7):440-6.
    View in: PubMed
    Score: 0.016
  49. Two-hour seven-sample oral glucose tolerance test and meal protocol: minimal model assessment of beta-cell responsivity and insulin sensitivity in nondiabetic individuals. Diabetes. 2005 Nov; 54(11):3265-73.
    View in: PubMed
    Score: 0.015
  50. Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals. Diabetes. 2005 Aug; 54(8):2447-52.
    View in: PubMed
    Score: 0.015
  51. Insulin release in impaired glucose tolerance: oral minimal model predicts normal sensitivity to glucose but defective response times. Diabetes. 2002 Feb; 51 Suppl 1:S227-33.
    View in: PubMed
    Score: 0.012
  52. GLP-1-induced alterations in the glucose-stimulated insulin secretory dose-response curve. Am J Physiol Endocrinol Metab. 2001 Aug; 281(2):E242-7.
    View in: PubMed
    Score: 0.011
  53. Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity. Diabetes. 2001 Jan; 50(1):150-8.
    View in: PubMed
    Score: 0.011
  54. Failure of physiological plasma glucose excursions to entrain high-frequency pulsatile insulin secretion in type 2 diabetes. Diabetes. 2000 Aug; 49(8):1334-40.
    View in: PubMed
    Score: 0.010
  55. Roles of insulin resistance and obesity in regulation of plasma insulin concentrations. Am J Physiol Endocrinol Metab. 2000 Mar; 278(3):E501-8.
    View in: PubMed
    Score: 0.010
  56. Metabolic effects of short-term elevations of plasma cortisol are more pronounced in the evening than in the morning. J Clin Endocrinol Metab. 1999 Sep; 84(9):3082-92.
    View in: PubMed
    Score: 0.010
  57. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998 Feb 01; 128(3):176-85.
    View in: PubMed
    Score: 0.009
  58. Insulin acutely suppresses glucose production by both peripheral and hepatic effects in normal dogs. Am J Physiol. 1998 02; 274(2):E346-56.
    View in: PubMed
    Score: 0.009
  59. Evidence that insulin can directly inhibit hepatic glucose production. Diabetologia. 1997 Nov; 40(11):1300-6.
    View in: PubMed
    Score: 0.009
  60. A novel point mutation in the insulin gene giving rise to hyperproinsulinemia. J Clin Endocrinol Metab. 1997 May; 82(5):1629-31.
    View in: PubMed
    Score: 0.008
  61. Late post-prandial hypoglycaemia as the sole presenting feature of secreting pancreatic beta-cell adenoma in a subtotally gastrectomized patient. Eur J Endocrinol. 1997 Jan; 136(1):96-9.
    View in: PubMed
    Score: 0.008
  62. Alterations in the ultradian oscillations of insulin secretion and plasma glucose in aging. Diabetologia. 1996 May; 39(5):564-72.
    View in: PubMed
    Score: 0.008
  63. Clinical phenotypes, insulin secretion, and insulin sensitivity in kindreds with maternally inherited diabetes and deafness due to mitochondrial tRNALeu(UUR) gene mutation. Diabetes. 1996 Apr; 45(4):478-87.
    View in: PubMed
    Score: 0.008
  64. Abnormal temporal patterns of glucose tolerance in obesity: relationship to sleep-related growth hormone secretion and circadian cortisol rhythmicity. J Clin Endocrinol Metab. 1994 Dec; 79(6):1797-805.
    View in: PubMed
    Score: 0.007
  65. Abnormalities in the ultradian oscillations of insulin secretion and glucose levels in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1992 Jul; 35(7):681-9.
    View in: PubMed
    Score: 0.006
  66. Persistence of oscillatory insulin secretion in denervated islet cell autografts. Transplantation. 1991 Sep; 52(3):574-6.
    View in: PubMed
    Score: 0.006
  67. Hypoglycemia due to surreptitious injection of insulin. Identification of insulin species by high-performance liquid chromatography. Diabetes Care. 1991 Jul; 14(7):544-7.
    View in: PubMed
    Score: 0.006
  68. Nocturnal elevation of glucose levels during fasting in noninsulin-dependent diabetes. J Clin Endocrinol Metab. 1991 Feb; 72(2):444-54.
    View in: PubMed
    Score: 0.005
  69. Effects of weight loss and reduced hyperglycemia on the kinetics of insulin secretion in obese non-insulin dependent diabetes mellitus. J Clin Endocrinol Metab. 1990 Jun; 70(6):1594-602.
    View in: PubMed
    Score: 0.005
  70. Pattern of postprandial carbohydrate metabolism and effects of portal and peripheral insulin delivery. Diabetes. 1990 Feb; 39(2):142-8.
    View in: PubMed
    Score: 0.005
  71. Effects of aging on insulin secretion. Diabetes. 1989 Dec; 38(12):1549-56.
    View in: PubMed
    Score: 0.005
  72. Oscillations in insulin secretion during constant glucose infusion in normal man: relationship to changes in plasma glucose. J Clin Endocrinol Metab. 1988 Aug; 67(2):307-14.
    View in: PubMed
    Score: 0.005
  73. Proinsulin radioimmunoassay in the evaluation of insulinomas and familial hyperproinsulinemia. Metabolism. 1986 Dec; 35(12):1137-46.
    View in: PubMed
    Score: 0.004
  74. Lack of direct inhibition of insulin secretion by exogenous insulin in the canine pancreas. J Clin Invest. 1986 Nov; 78(5):1193-8.
    View in: PubMed
    Score: 0.004
  75. Natural history of intrahepatic canine islet cell autografts. J Clin Invest. 1986 Nov; 78(5):1339-48.
    View in: PubMed
    Score: 0.004
  76. In vivo pulsatility of pancreatic islet peptides. Am J Physiol. 1986 Aug; 251(2 Pt 1):E215-26.
    View in: PubMed
    Score: 0.004
  77. Long-term follow-up of canine segmental pancreatic autografts. Diabetes. 1985 Feb; 34(2):174-8.
    View in: PubMed
    Score: 0.004
  78. Pancreatic hormone profiles and metabolism posthepatectomy in the dog. Evidence for a hepatotrophic role of insulin, glucagon, and pancreatic polypeptide. Gastroenterology. 1984 Sep; 87(3):679-87.
    View in: PubMed
    Score: 0.003
  79. The effects of biosynthetic human proinsulin on carbohydrate metabolism. Diabetes. 1984 Aug; 33(8):762-70.
    View in: PubMed
    Score: 0.003
  80. Familial hyperinsulinemia due to a structurally abnormal insulin. Definition of an emerging new clinical syndrome. N Engl J Med. 1984 May 17; 310(20):1288-94.
    View in: PubMed
    Score: 0.003
  81. Human insulin B24 (Phe----Ser). Secretion and metabolic clearance of the abnormal insulin in man and in a dog model. J Clin Invest. 1984 May; 73(5):1351-8.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.